Friedreich's Ataxia Market Size, Share, Industry, Forecast and Outlook (2023-2030)

Market Overview:
The global Friedreich's ataxia treatment market achieved a valuation of US$ YY billion in 2022 and is anticipated to reach US$ YY billion by 2030, exhibiting a robust CAGR of YY% during the forecast period from 2023 to 2030.

The global Friedreich's ataxia treatment market has experienced substantial growth and transformative changes over the years, driven by various factors. Friedreich's ataxia is a rare genetic degenerative condition that affects the cerebellar region of the brain, peripheral nerves, and the spinal cord. Typically, it manifests in children and teenagers and progresses over time, leading to unstable movements and nerve damage-induced loss of sensation as the condition worsens.

Government investments and research initiatives, particularly in developing economies, will continue to promote the use of innovative medications like omaveloxolone or propranolol, thereby bolstering the global Friedreich's ataxia treatment market. Multiple researchers are actively developing these innovative medications, which are currently undergoing clinical trials.

Market Dynamics: Drivers & Restraints:
Growing Collaborations and Acquisitions:
Developed economies have witnessed significant advancements in their healthcare sectors, driven by substantial investments, high income levels, and infrastructure development. Several countries have observed a rising demand for Friedreich's ataxia treatment due to increased research activities. Collaborations, acquisitions, and product launches with technological advancements across different countries will be a critical factor driving market growth.

For instance, on January 9, 2023, Voyager Therapeutics, Inc. and Neurocrine Biosciences, Inc. formed a strategic partnership to advance various gene therapies for neurological diseases. This collaboration includes Voyager's preclinical GBA1 gene therapy program, integrating a GBA1 gene replacement payload with new capsids from Voyager's TRACERTM (Tropism Redirection of AAV via Cell-type-specific Expression of RNA) platform.

Additionally, a collaborative drug discovery study in Friedreich's ataxia (FA) was initiated, led by Dr. Michele Lufino and involving Ataxia UK, the University of Oxford, Pfizer Inc., UCL, and Imperial College London. This partnership brings together university researchers and Pfizer experts to work on innovative solutions for FA.

The increasing use of novel technology and product launches for research purposes, along with the rising cases of Friedreich's ataxia and ongoing research for innovative treatment product development, will significantly drive the growth of the Friedreich's ataxia treatment market.
For more details on this report - https://www.datamintelligence.com/download-sample/friedreichs-ataxia-market

Market Segment Analysis:
The global Friedreich's ataxia treatment market is segmented based on medications, route of administration, distribution channels, and regions. The omaveloxolone segment accounted for approximately 61% of the market share.

Omaveloxolone, developed by Reata Pharmaceuticals, Inc., is an orally active, semi-synthetic triterpenoid medication that enhances antioxidant activity. It is used to treat Friedreich's ataxia, a condition that affects muscles and nerves. Omaveloxolone activates the Nrf2 pathway, which is suppressed in Friedreich's ataxia patients, leading to oxidative stress, mitochondrial dysfunction, and cell damage. The U.S. Food and Drug Administration (FDA) approved omaveloxolone for Friedreich's ataxia treatment in February 2023.

Geographical Penetration:
North America accounted for approximately 38% of the market share in 2022. Manufacturers in North America have significant opportunities to expand their operations due to the increasing demand for Friedreich's ataxia treatment in the healthcare sector. The region has numerous producers and suppliers, and its rapid economic growth has driven industrial production, thus increasing the demand for Friedreich's ataxia treatment.

The growth in healthcare expenditure, research studies, technological advancements, diverse medicines, and the establishment of biopharmaceutical and biotechnology businesses in the region contribute to the growth of the Friedreich's ataxia treatment market. The market in North America is expanding as people become more aware of various newly approved medications, highlighting the region's dominant position in the global market.

North America remains a key player in the global Friedreich's ataxia treatment market, with the United States leading the way. Government initiatives supporting infrastructure development, investment, and advancements have stimulated the demand for Friedreich's ataxia treatment in the United States, where various initiatives and research activities are being actively executed.

COVID-19 Impact Analysis:
The COVID-19 pandemic, which began in early 2020, had a significant impact on various industries, including the global Friedreich's ataxia treatment market. The pandemic's broad lockdowns and restrictions disrupted efforts worldwide. Major medical and biotechnology industries shifted their focus to managing COVID-19, leading to a decline in demand for Friedreich's ataxia treatment. However, several research studies have been initiated, and companies have resumed trials for their product efficiency. Overall, the pandemic's impact on the global Friedreich's ataxia treatment market is expected to be relatively moderate, with the market continuing to grow steadily due to ongoing research for innovative medications.

Key Developments:

On August 14, 2023, initial findings from Design Therapeutics, Inc.'s phase one multiple-ascending dose (MAD) clinical study of DT-216 in patients with Friedreich ataxia (FA) were released. DT-216 was well tolerated and increased frataxin (FXN) mRNA levels in skeletal muscle biopsies in a dose-dependent and statistically significant manner.
On May 31, 2023, PTC Therapeutics released topline data from the MOVE-FA study of vatiquinone in individuals with Friedreich ataxia. Although the primary goal of the trial was not achieved, vatiquinone showed significant improvements in essential disease endpoints and subscales.
On November 29, 2022, Minoryx Therapeutics published a Phase 2 double-blind, randomized, placebo-controlled study examining the impact of leriglitazone on patients with Friedreich's ataxia (FRAMES study) in Neurology Genetics.
Competitive Landscape:
Major global players in the market include Reata Pharmaceuticals, Inc., Retrotope Inc., Minoryx Therapeutics, Design Therapeutics, Inc., PTC Therapeutics, Lexeo Therapeutics, Inc., Larimar Therapeutics, Inc., Metro International Biotech, LLC, Astellas Gene Therapies, Inc., and Voyager Therapeutics, Inc., among others.

Trending Titles:

Fabry Disease Treatment Market: https://www.datamintelligence.com/research-report/fabry-disease-treatment-market

Wilsons Disease Treatment Market: https://www.datamintelligence.com/research-report/wilsons-disease-treatment-market

Cystinosis Treatment Market:
https://www.datamintelligence.com/research-report/cystinosis-treatment-market

Media Contact
Company: Sai Kiran
Email: info@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com/

DATAM INTELLIGENCE 4MARKET RESEARCH LLP
HABSIGUDA, IDA - UPPAL

About DataM Intelligence
DataM Intelligence 4Market Research is a Market Research firm that provides end-to-end business solutions to organizations from Research to Consulting. We at DataM Intelligence leverage our top trademark trends, insights, and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of Syndicate Reports & and; Customized Reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries, catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.